Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHGV0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,901
Award facts
- Contract value 100% obligated
- $37,901.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $37,901.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, awarded on December 19, 2025, with an ultimate completion date of January 13, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR, which was established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative on November 13, 2025.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to support the Department of Defense's pharmaceutical supply needs globally. DMS Pharmaceutical Group's IDC, with a ceiling value of $499,999,999 and completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. Xolair, an immunosuppressant biologic agent, aligns with DMS Pharmaceutical Group's established product portfolio of specialty pharmaceuticals supplied to federal defense agencies. The contractor holds no identified subcontractor relationships and has demonstrated substantial performance capability through numerous prior delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FHGV0?
SPE2DR26FHGV0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FHGV0 worth?
The government has obligated $37,901 on SPE2DR26FHGV0.
Is contract SPE2DR26FHGV0 an order under another contract?
Yes. SPE2DR26FHGV0 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGV0 competed?
The extent of competition for SPE2DR26FHGV0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award